Spinal muscular atrophy: an update on therapeutic progress.
Biochim Biophys Acta
; 1832(12): 2180-90, 2013 Dec.
Article
en En
| MEDLINE
| ID: mdl-23994186
Palabras clave
ALS; ASO; Antisense oligonucleotide; BBB; CREB; FDA; Food and Drug Administration; GSK-3; Genetic disease therapy; HDAC; ICV; IGF-1; IP; ISS-N1; ISS-N2; IV; JAK; Janus kinase; N-methyl d-aspartic acid; NMDA; NSAID; SAHA; SC; SMA; SMA therapeutics; SMN; STAT5; Spinal muscular atrophy; Splicing; Survival motor neuron; T-cell restricted intracellular antigen 1; TIA1; TSA; VPA; amyotrophic lateral sclerosis; antisense oligonucleotide; blood brain barrier; cyclic AMP response element binding protein; glycogen synthase kinase 3; heterogenous ribonucleoprotein A1; histone deacetylase; hnRNP A1; insulin-like growth factor 1; intracerebroventricular; intraperitoneal; intravascular; intronic splicing silencer N1; intronic splicing silencer N2; non-steroidal anti-inflammatory drug; scAAV; self-complimentary adeno-associated virus; signal transducer and activator of transcription 5; small nuclear ribonucleoprotein; snRNP; spinal muscular atrophy; subcutaneous; suberoylanilide hydroxamic acid; survival motor neuron; trichostatin A; valproic acid
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Atrofia Muscular Espinal
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Biochim Biophys Acta
Año:
2013
Tipo del documento:
Article
País de afiliación:
Estados Unidos